Skip Navigation


Cardiovascular Research Advance Access first published online on May 31, 2008
This version [Corrected Proof] published online on June 17, 2008
Cardiovascular Research, doi:10.1093/cvr/cvn139
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
79/4/706    most recent
cvn139v2
cvn139v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Miyake, T.
Right arrow Articles by Morishita, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyake, T.
Right arrow Articles by Morishita, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Inhibition of anastomotic intimal hyperplasia using a chimeric decoy strategy against NF{kappa}B and E2F in a rabbit model

Takashi Miyake1, Motokuni Aoki2 and Ryuichi Morishita1,*

1 Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan
2 Department of Physical Therapy, Morinomiya University of Medical Sciences, Osaka, Japan

* Corresponding author. Tel: +81 6 6879 3406; fax: +81 6 6879 3409. E-mail address: morishit{at}cgt.med.osaka-u.ac.jp

Aims: Neointimal formation remains a major limitation after arterial reconstruction. To overcome this problem, we focused on two important transcription factors, nuclear factor-kappaB (NF{kappa}B) and E2F. The purpose of this study was to determine the effects of simultaneous inhibition of these transcription factors on the formation of neointimal hyperplasia.

Methods and results: We employed chimeric decoy oligodeoxynucleotides (ODN) to inhibit both NF{kappa}B and E2F simultaneously, and examined the effects of chimeric decoy ODN on the proliferation and migration of cultured vascular cells and on the formation of neointimal hyperplasia using prosthetic graft placement in a rabbit hypercholesterolemia model. Our in vitro study demonstrated that transfection of chimeric decoy ODN inhibited platelet-derived growth factor (PDGF)-induced proliferation and migration of vascular smooth muscle cells, whereas endothelial cell proliferation was not inhibited. In an in vivo study, treatment with chimeric decoy ODN significantly inhibited proximal and distal anastomotic intimal hyperplasia, and accelerated re-endothelialization. {alpha}-Smooth muscle actin ({alpha}-SMA)-positive cell proliferation was inhibited at the anastomotic sites. Expression of PDGF-BB and PDGF receptor-β was also suppressed by chimeric decoy ODN, resulting in a reduction of {alpha}-SMA-positive cell accumulation. In addition, chimeric decoy ODN treatment inhibited macrophage accumulation, which was accompanied by a reduction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1 gene expression.

Conclusion: The present study demonstrates the feasibility of chimeric decoy ODN treatment for preventing neointimal formation. This strategy might be useful to improve the clinical outcome after arterial reconstruction.

KEYWORDS Gene therapy; NF{kappa}B; E2F; Restenosis; Cardiovascular surgery

Time for primary review: 25 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.